Company intelligence / Profile preview

NIBEC

Seoul, Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

NIBEC has advanced a peptide-based therapy (NP-201) for pulmonary fibrosis into phase 2 and has completed a successful clinical study of its bone regeneration material in China, seeking NMPA approval; it sells CE-marked and commercialized dental bone and oral care biomaterial products[6][7].

Therapeutic areas: RheumatologyPulmonologyOther
Modalities: PeptidesSmall moleculeProteinBiomaterial
Industry: Biotech

Partnerships

$435M license agreement (2025) with undisclosed US biotech (for NP-201)[6]

Beyond the preview

Go deeper on NIBEC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NIBEC.

Explore the full profile